Biocryst Pharmaceuticals Stock Performance
| BCRX Stock | USD 7.53 0.07 0.92% |
The firm shows a Beta (market volatility) of 2.17, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, BioCryst Pharmaceuticals will likely underperform. At this point, BioCryst Pharmaceuticals has a negative expected return of -0.0243%. Please make sure to confirm BioCryst Pharmaceuticals' maximum drawdown, as well as the relationship between the skewness and day typical price , to decide if BioCryst Pharmaceuticals performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days BioCryst Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly strong basic indicators, BioCryst Pharmaceuticals is not utilizing all of its potentials. The current stock price disturbance, may contribute to short-term losses for the investors. ...more
Actual Historical Performance (%)
One Day Return (0.92) | Five Day Return (4.68) | Year To Date Return 24.05 | Ten Year Return (26.39) | All Time Return 15.85 |
1 | Disposition of 100000 shares by Jon Stonehouse of BioCryst Pharmaceuticals at 10.38 subject to Rule 16b-3 | 09/24/2024 |
2 | Enanta Pharmaceuticals Surges 5.6 percent Is This an Indication of Further Gains | 10/02/2024 |
3 | How Much Upside is Left in BioCryst Wall Street Analysts Think 79.5 | 10/23/2024 |
4 | Vanguard Group Incs Strategic Acquisition in BioCryst Pharmaceuticals Inc | 11/05/2024 |
5 | Drugmaker eyes billion-dollar pill | 11/06/2024 |
6 | Acquisition by Jon Stonehouse of 10000 shares of BioCryst Pharmaceuticals subject to Rule 16b-3 | 11/08/2024 |
7 | BioCrysts SWOT analysis stock outlook amid orladeyo success, pipeline shifts | 11/12/2024 |
8 | BioCryst Launches ORLADEYO in Ireland | 11/18/2024 |
9 | Segall Bryant Hamill LLC Sells 36,105 Shares of BioCryst Pharmaceuticals, Inc. | 11/21/2024 |
10 | Market Sentiment Around Loss-Making BioCryst Pharmaceuticals, Inc. | 11/27/2024 |
11 | Acquisition by Milano Vincent of 750 shares of BioCryst Pharmaceuticals at 7.5 subject to Rule 16b-3 | 11/29/2024 |
12 | BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635 | 12/04/2024 |
13 | BNP Paribas Financial Markets Has 3.78 Million Stake in BioCryst Pharmaceuticals, Inc. - MarketBeat | 12/05/2024 |
| Begin Period Cash Flow | 306.2 M |
BioCryst |
BioCryst Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 792.00 in BioCryst Pharmaceuticals on September 17, 2024 and sell it today you would lose (39.00) from holding BioCryst Pharmaceuticals or give up 4.92% of portfolio value over 90 days. BioCryst Pharmaceuticals is currently does not generate positive expected returns and assumes 3.3103% risk (volatility on return distribution) over the 90 days horizon. In different words, 29% of stocks are less volatile than BioCryst, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
BioCryst Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for BioCryst Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as BioCryst Pharmaceuticals, and traders can use it to determine the average amount a BioCryst Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0073
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | BCRX |
Estimated Market Risk
| 3.31 actual daily | 29 71% of assets are more volatile |
Expected Return
| -0.02 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.01 actual daily | 0 Most of other assets perform better |
Based on monthly moving average BioCryst Pharmaceuticals is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of BioCryst Pharmaceuticals by adding BioCryst Pharmaceuticals to a well-diversified portfolio.
BioCryst Pharmaceuticals Fundamentals Growth
BioCryst Stock prices reflect investors' perceptions of the future prospects and financial health of BioCryst Pharmaceuticals, and BioCryst Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on BioCryst Stock performance.
| Return On Equity | -19.25 | ||||
| Return On Asset | -0.0425 | ||||
| Profit Margin | (0.30) % | ||||
| Operating Margin | 0.07 % | ||||
| Current Valuation | 2.04 B | ||||
| Shares Outstanding | 207.13 M | ||||
| Price To Earning | (7.11) X | ||||
| Price To Book | 56.59 X | ||||
| Price To Sales | 3.78 X | ||||
| Revenue | 331.41 M | ||||
| Gross Profit | 10.94 M | ||||
| EBITDA | (116.33 M) | ||||
| Net Income | (226.54 M) | ||||
| Cash And Equivalents | 417.48 M | ||||
| Cash Per Share | 2.24 X | ||||
| Total Debt | 848.71 M | ||||
| Debt To Equity | 2.40 % | ||||
| Current Ratio | 5.19 X | ||||
| Book Value Per Share | (2.26) X | ||||
| Cash Flow From Operations | (95.14 M) | ||||
| Earnings Per Share | (0.61) X | ||||
| Market Capitalization | 1.56 B | ||||
| Total Asset | 516.96 M | ||||
| Retained Earnings | (1.68 B) | ||||
| Working Capital | 345.98 M | ||||
| Current Asset | 65.99 M | ||||
| Current Liabilities | 64.45 M | ||||
About BioCryst Pharmaceuticals Performance
Evaluating BioCryst Pharmaceuticals' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if BioCryst Pharmaceuticals has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if BioCryst Pharmaceuticals has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 2.2 K | 2.4 K | |
| Return On Tangible Assets | (0.44) | (0.46) | |
| Return On Capital Employed | (0.28) | (0.30) | |
| Return On Assets | (0.44) | (0.46) | |
| Return On Equity | 0.50 | 0.52 |
Things to note about BioCryst Pharmaceuticals performance evaluation
Checking the ongoing alerts about BioCryst Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for BioCryst Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| BioCryst Pharmaceuticals generated a negative expected return over the last 90 days | |
| BioCryst Pharmaceuticals has high historical volatility and very poor performance | |
| BioCryst Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 331.41 M. Net Loss for the year was (226.54 M) with profit before overhead, payroll, taxes, and interest of 10.94 M. | |
| BioCryst Pharmaceuticals currently holds about 417.48 M in cash with (95.14 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.24. | |
| BioCryst Pharmaceuticals has a frail financial position based on the latest SEC disclosures | |
| Over 86.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from news.google.com: BNP Paribas Financial Markets Has 3.78 Million Stake in BioCryst Pharmaceuticals, Inc. - MarketBeat |
- Analyzing BioCryst Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether BioCryst Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining BioCryst Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating BioCryst Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of BioCryst Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of BioCryst Pharmaceuticals' stock. These opinions can provide insight into BioCryst Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for BioCryst Stock Analysis
When running BioCryst Pharmaceuticals' price analysis, check to measure BioCryst Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioCryst Pharmaceuticals is operating at the current time. Most of BioCryst Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of BioCryst Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioCryst Pharmaceuticals' price. Additionally, you may evaluate how the addition of BioCryst Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.